Keyphrases
Confidence Interval
100%
Gemcitabine
100%
Phase II Trial
100%
Metastatic Breast Cancer
100%
Pemetrexed
100%
NCCTG
100%
Overall Response Rate
40%
Neutropenia
40%
Taxanes
40%
Anthracyclines
40%
Febrile Neutropenia
40%
Phase II Study
20%
1-year Survival
20%
Median Time
20%
Partial Response
20%
Hematotoxicity
20%
Thrombocytopenia
20%
Dyspnea
20%
Stable Disease
20%
Rash
20%
Treatment Toxicity
20%
Living Patients
20%
Myelosuppression
20%
Median Survival Time
20%
Time to Progression
20%
Anorexia
20%
Neoadjuvant Setting
20%
Metastatic Setting
20%
Pharmacology, Toxicology and Pharmaceutical Science
Phase II Trials
100%
Metastatic Breast Cancer
100%
Gemcitabine
100%
Pemetrexed
100%
Neutropenia
50%
Anthracycline
50%
Febrile Neutropenia
50%
Taxane
50%
Survival Rate
25%
Thrombocytopenia
25%
Dyspnea
25%
Rash
25%
Bone Marrow Suppression
25%
Median Survival Time
25%
Anorexia
25%
Diseases
25%